

---

**RAPID-AMERICAN ASBESTOS PERSONAL INJURY LIQUIDATING TRUST**

1000 N. West Street, Suite 300

Wilmington, DE 19801

To: Claimant Law Firms

Re: Rapid-American Asbestos Personal Injury Liquidating Trust

Date: December 15, 2023

You are receiving this letter because your firm submitted claims to the Rapid-American Asbestos Personal Injury Liquidating Trust (“Trust”) prior to the November 28, 2023 Trust Filing Deadline.<sup>1</sup> All claims must meet the very specific exposure requirements to be paid. Claimants are required to demonstrate meaningful and credible exposure prior to June 1, 1967 to an asbestos-containing product manufactured, sold, supplied, produced, distributed, released, advertised or marketed by The Philip Carey Manufacturing Company.

Per Section 4.3(a)(2) of the Trust Distribution Procedures (“TDP”), the Trust shall determine whether a claim meets the medical/exposure criteria for one of the Trust Disease Levels, advise the claimant of its determination, and if approved tender an offer of payment to the claimant. Once an offer is accepted and a properly executed release is returned, the claim shall be paid by the Trust pursuant to Sections 2 and 3 of the TDP.

**As set forth in the Trust opening letter, per Section 4.2 of the TDP, all claim deficiencies must be resolved prior to the latter of May 28, 2024 or six months from the date the Trust sends the claimant an initial deficiency notification.<sup>2</sup> If all claim deficiencies are not resolved prior to the deadline, the claim shall not be payable. All Schedule F claims are subject to the May 28, 2024 deadline.**

**A claimant who received an intake deficiency notice or a review deficiency notice on or prior to November 28, 2023 has until May 28, 2024 to cure those deficiencies as well as any subsequently issued review deficiency notices.**

**A claimant who has received or receives an intake deficiency notice subsequent to November 28 has six months from the date of that notice to cure all deficiencies. This includes curing the intake deficiency as well as any subsequent claim review deficiencies**

**Similarly, a claimant who passed intake review but received or receives review deficiency notices subsequent to November 28 has six months from the date of the initial review deficiency notice to cure all deficiencies.**

The Trust has begun the review process and will begin to issue releases to payable claims in the next quarter. Per Section 5.3 of the TDP, a claim will be deemed withdrawn if a release is not

---

<sup>1</sup> Per Section 4.2 of the TDP, if a Claimant does not submit a proof of claim form prior to the Trust Filing Deadline, the claim shall not be payable.

<sup>2</sup> Intake deficiencies and review deficiencies are both initial deficiencies for all purposes herein.

returned within six months of receipt. Exceptions will be made for claimants who demand arbitration within that six month period, with the understanding that costs of arbitration will be shared equally by claimant and the Trust. Exceptions may also be made, in the sole discretion of the Trustee, on a case by case basis, for claims in probate, provided the Trustee is satisfied that duly authorized execution of a release is imminent.

The amount of a claimant's pro rata distribution cannot be calculated until the Trust knows the number of accepted offers in each disease category. Offers will be made in scheduled value amounts, and payment will be subject to the subsequently determined pro rata distribution.

If there are any questions regarding the above, please email [claimantrelations@delcpf.com](mailto:claimantrelations@delcpf.com), or call (800) 708-8925.

Sincerely,

The Rapid-American Asbestos Personal Injury Liquidating Trustee